First People's Hospital of Chenzhou
31
6
6
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 31 trials
100.0%
+13.5% vs industry average
23%
7 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (31)
Combined Oscillation-Volume guarantEe Study
Role: collaborator
Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction
Role: collaborator
Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter, Prospective Study
Role: collaborator
HVA vs IA/DA or VA in the Treatment of ND HR-AML
Role: collaborator
Validation of an AI-Assisted Pancreatic EUS System for Training Improvement: a Prospective, Multi-Center, Randomized Trial
Role: collaborator
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Role: collaborator
Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT
Role: collaborator
Preoperative Sildenafil Administration for Hepatectomy
Role: lead
Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
Role: collaborator
Effect of Tourniquet Binding of Cervical on the Blood Volume of Amniotic Fluid in Cesarean Section
Role: lead
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT
Role: collaborator
Novel Local Infiltration Anesthesia for Radial Artery Cannulation.
Role: lead
Cerebrospinal Fluid Gravity Correlation Analysis
Role: lead
Dexmedetomidine Reduce Postoperative Pain of C-section
Role: lead
VAH Versus VA for Salvage Therapy of R/R-AML
Role: collaborator
Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML
Role: collaborator
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT
Role: collaborator
Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML
Role: collaborator
BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT
Role: collaborator
G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
Role: collaborator